- Home
- Life Sciences
- Breast Cancer Liquid Biopsy
Breast Cancer Liquid Biopsy Market Research Report – Segmented By Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2030.
-
Published date -30th Jan 2024
-
Formats -PDF, CSV
-
Region -Global
Breast Cancer Liquid Biopsy Market Size & CAGR in 2021:
The global breast cancer liquid biopsy market is estimated to have a CAGR of 15.2% from 2021 to 2028. The market size is projected to reach USD 1.5 billion by 2028.
COVID-19 Impact on the Breast Cancer Liquid Biopsy Market:
The COVID-19 pandemic has had a mixed impact on the breast cancer liquid biopsy market. While there were disruptions in supply chains and clinical trials, the increased focus on healthcare and diagnostics has also driven growth in the market.
Breast Cancer Liquid Biopsy Dynamics:
The breast cancer liquid biopsy market is witnessing significant growth due to factors such as increasing prevalence of breast cancer, advancements in liquid biopsy technologies, and rising demand for non-invasive diagnostic methods.
Segments and Related Analysis:
The breast cancer liquid biopsy market is segmented based on technology, application, and end user. Technologies include PCR, NGS, and others. Applications include early screening, treatment monitoring, and recurrence monitoring.
By Region Analysis:
The breast cancer liquid biopsy market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America currently leads the market due to technological advancements and high healthcare spending.
Key Market Players and Competitive Landscape:
Some key players in the breast cancer liquid biopsy market include Guardant Health, F. Hoffmann-La Roche, Bio-Rad Laboratories, QIAGEN, and Thermo Fisher Scientific. The market is competitive with companies focusing on product innovation and strategic partnerships.
Recent Happenings in the Breast Cancer Liquid Biopsy Market:
In recent developments, Guardant Health announced a new liquid biopsy test for breast cancer detection, while F. Hoffmann-La Roche launched a liquid biopsy platform for comprehensive cancer profiling. These advancements are expected to drive further growth in the market.
